Synageva BioPharma Highlights Sebelipase Alfa And LAL Deficiency Data At The Lysosomal Disease Network (LDN) WORLD Symposium
Published: Feb 14, 2014
LEXINGTON, Mass.--(BUSINESS WIRE)--Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, today announced sebelipase alfa and lysosomal acid lipase deficiency (LAL Deficiency) data from oral and poster presentations at the LDN WORLD Symposium being held February 11-13 in San Diego, California.
Help employers find you! Check out all the jobs and post your resume.